BioCentury | Oct 19, 2019
Product Development

How GSK has rebuilt its oncology pipeline from the ground up

...through the Tesaro acquisition, and created an agonist antibody against OX40 in-house. The TIM-3 mAb TSR-022...
BioCentury | Feb 8, 2019
Company News

Via Merck KGaA Deal, GSK adds to growing immuno-oncology pipeline

...gained an immuno-oncology portfolio that includes dostarlimab (TSR-042), a PD-1 inhibitor in Phase III testing; TSR-022...
BioCentury | Feb 5, 2019
Company News

Via Merck KGaA deal, GSK adds to growing immuno-oncology pipeline

...gained an immuno-oncology portfolio that includes dostarlimab (TSR-042), a PD-1 inhibitor in Phase III testing; TSR-022...
BioCentury | Dec 7, 2018
Finance

Taking Tesaro

...gains an immuno-oncology portfolio that includes dostarlimab (TSR-042), a PD-1 inhibitor in Phase III testing; TSR-022...
BioCentury | Dec 7, 2018
Company News

GSK gains Zejula, immuno-oncology portfolio in $5.1B Tesaro takeout

...dostarlimab, GSK will also receive a handful of immuno-oncology therapies. These include Phase I therapy TSR-022...
...LSE:GSK; NYSE:GSK), London, U.K. Tesaro Inc. (NASDAQ:TSRO), Waltham, Mass. Business: Cancer Allison Johnson Lynparza, olaparib (AZD2281, KU-0059436, MK-7339) TSR-022 TSR-033 TSR-042...
BioCentury | Dec 4, 2018
Company News

GSK gains Zejula, immuno-oncology pipeline in $5.1B Tesaro acquisition

...dostarlimab, GSK will also receive a handful of immuno-oncology therapies. These include Phase I therapy TSR-022...
...see "Zai Gains Hong Kong Approval of PARP Inhibitor Zejula" ). Allison Johnson Lynparza, olaparib (AZD2281, KU-0059436, MK-7339) TSR-022 TSR-033 TSR-042...
BioCentury | Nov 17, 2018
Company News

Tesaro stock rebounds on takeout report

...previous PD-1 inhibitors (see "Investors Ding Tesaro Despite Responses for Combo in NSCLC" ). Elizabeth S. Eaton TSR-022 TSR-042...
BioCentury | Nov 16, 2018
Clinical News

Tesaro combo leads to partial responses in NSCLC patients

...NASDAQ:TSRO) reported data from the open-label Phase I AMBER trial showing that a combination of TSR-022...
...following anti-PD-1 treatment. The company said all four of the responses occurred in PD-L1-positive patients. TSR-022...
...data from the melanoma cohort are expected next year. Tesaro has exclusive, worldwide rights to TSR-022...
BioCentury | Nov 10, 2018
Clinical News

Investors ding Tesaro despite responses for combo in NSCLC

...NASDAQ:TSRO) reported data Friday from the Phase I AMBER trial showing that a combination of TSR-022...
...The move translated to a loss of about $320 million in the company's market cap. TSR-022...
...data from the NSCLC cohort and data from the melanoma cohort are expected next year. Brian Moy TSR-022 TSR-042...
Items per page:
1 - 9 of 9